Atai Life Sciences ATAI Stock Forecast 2023

Atai Life Sciences ATAI Stock Forecast 2023: Latest Price

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focus on various mental health disorders. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

ATAI Stock 12 Months Target

ATAI Target Price, 12 Months	$14.4
EF Hutton	$15
Credit Suisse	$9
HC Wainwright & Co.	$20
Citigroup	$10
Loop Capital	$18

Atai Life Sciences ATAI Stock Forecast 2023: Latest News

1. Key clinical pipeline and company updates were delivered by Atai Life Sciences (ATAI), a clinical-stage biopharmaceutical firm looking to revolutionize the treatment of mental health issues. “The dosing of the first patient in the phase 2b study of RL-007 in CIAS earlier this quarter exemplifies the execution capabilities of our team as we advance our programs into later-stage clinical studies,” said Florian Brand, CEO and Co-Founder of Atai.
2. As part of a strategic review, Atai Life Sciences announced a 30% reduction in staff while also providing other clinical and business updates. Atai stated that the decision to cut employees was made in order to improve operational efficiency and focus after conducting a comprehensive evaluation of its pipeline. According to the business, non-clinical development, administration, and general labor reduction will account for the majority of the cost savings. Atai anticipates that its cash runway will now reach H1 2026. The medicine PCN-101 (R-ketamine) by Atai’s majority-owned subsidiary Perception Neuroscience failed to achieve the primary objective of a phase 2a trial in treatment-resistant depression in January, which caused the stock to plummet.

Atai Life Sciences ATAI Stock Forecast 2023: Fundamentals

Atai Life Sciences Nv (NASDAQ: ATAI) announced Q4 2022 earnings per share (EPS) of -$0.29 on March 29, 2023, an increase of 53.23% from the previous quarter. The total revenue for the quarter for Atai Life Sciences Nv was -$45.01 million. Atai Life Sciences Nv’s earnings per share (EPS) during the same quarter last year were negative $0.62. Revenue of $38,000 during the fourth quarter of 2022 increased by 83.48% over the previous quarter. Atai Life Sciences Nv’s revenue for the same period the previous year was $230.00 thousand.

Atai Life Sciences Nv’s profits as of Q2 2023 have increased year over year. The annual revenue for Atai Life Sciences Nv was -$152.39 million. Atai Life Sciences Nv’s sales increased -98.86% year over year as of Q2 2023. This is 156.97 percentage points less than the 58.12% revenue growth rate for the US biotechnology industry. The yearly revenue for Atai Life Sciences Nv was $233.00 thousand.

• ATAI is generating a lower Return on Assets (-44.1%) than the US Biotechnology industry average (0.81%).
• ATAI’s ability to generate Return on Capital (-51.19%) has decreased compared to 3 years ago (-23.36%)

ATAI Life Sciences N.V. is estimated to report earnings on 05/15/2023. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.22. The reported EPS for the same quarter last year was $-0.24.

Atai Life Sciences Stock Technical Analysis

• 52 Week Range: 1.14 – 5.44
• Volume: 1,053,502
• Average Vol.(3m): 1,328,688
• Market Cap: 297.16M
• EPS: -0.979

When we examine the technicals, the stock appears to be highly bullish. The short-term period graph suggests a significant breakout potential, and when viewed over a one-day period, it still seems to be in the strongly buy zone. With MA 50 and MA 200 at 1.6 and 2.94, respectively, the moving averages appear to be in good shape. The ultimate oscillator is at 56.437 and the relative strength index is 59.746, indicating that the momentum oscillators are in the stock’s favor.

The MACD (12, 26) and ADX (14) are at 0.060 and 50.925, respectively, indicating an excellent purchase opportunity, which adds to the trends’ positive appearance. Even the volatility index is strong, showing that there is a sufficient interchange to support the positive oscillations.

ATAI Stock Forecast 2023: Macros

Medication development, production, and distribution are all handled by the pharmaceutical sector. The market has grown significantly over the past two decades, and pharmaceutical sales globally reached 1.42 trillion US dollars in 2016.

The pharmaceutical business, more than any other, depends heavily on research and development, with corporations investing up to 20% of sales earnings in R&D projects.

Pharmacists must carefully reevaluate their long-term decisions in sourcing, manufacturing, and supply chain in light of factors like the COVID-19 pandemic, inflation, geopolitics, new therapeutic modalities, and new ways of working.

The current emphasis on continuous improvement, including cost savings, quality assurance, and constant delivery readiness, may need to give way for operational leaders to longer-term external issues. They include a high rate of inflation, an increase in complexity and risk, as well as the interactions between these forces.

ATAI Stock Forecast 2023: Analysts’ Price Targets

1. EF Hutton: $15
2. Credit Suisse: $9
3. INDMoney: analysts offering 12-month price forecasts for ATAI Life Sciences NV (ATAI) have a share price target of $12.88. This median of the share price forecast represents a 662.13% upside from the latest price of $1.69 as of 11.04.23.
4. CNN: The 12 analysts offering 12-month price forecasts for ATAI Life Sciences NV have a median target of 11.00, with a high estimate of 21.00 and a low estimate of 5.10. The median estimate represents a +509.42% increase from the last price of 1.81.
5. NASDAQ: Based on analysts offering 12-month price targets for ATAI in the last 3 months. The average price target is $13.75 with a high estimate of $20 and a low estimate of $9.

Author: Pratyush Mengi

Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decisions.